Molecular Features Underlying Discordance Between Clinical and Genomic Risk Stratification in Localized Prostate Cancer in Over 280, 000 Patients

INTRODUCTION: Although the Decipher Genomic Classifier (GC) improves risk stratification beyond standard National Comprehensive Cancer Network (NCCN) risk groups, distinct clinical discordance exists between them. Herein, we interrogate specific adverse molecular features (AMFs) associated with genomic upgrading/downgrading relative to clinical risk and evaluate their overall long-term prognostic impact on treated patients. MATERIALS AND METHODS: The specific prevalence of four separate AMFs (TP53 status, PTEN inactivation, lower androgen receptor [AR] activity, and RB1 loss) was evaluated across GC and NCCN risk groups using biopsy data from 287,145 patients. Prognostic associations with distant metastasis (DM) were fully assessed in 15,109 patients with NCCN high and very high-risk disease. RESULTS: Decipher re-classified 21% of NCCN low and favorable intermediate-risk patients as high risk, while 33% of NCCN high-risk patients were GC-lower risk. AMF prevalence associated more strongly with GC than NCCN groups. TP53 mutant-like status, PTEN inactivation, and lower AR activity were associated with NCCN-GC discordance. Within the study cohort, a high GC score was associated with significantly increased risk of DM; AMFs independently predicted DM. Patients with at least one adverse AMF and a GC score >0.60 had a predicted 5-year DM probability of 17-25%, compared to 5% for those with favorable molecular profiles and a GC score ≤0.60. CONCLUSIONS: Individual AMFs are associated with the discordance between NCCN and GC risk classifications. In patients with NCCN high-risk disease, the GC score serves as a primary prognostic driver, while AMF profiling provides additive risk stratification within specific clinical GC strata.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2026-11-17
DOI
https://doi.org/10.1158/1078-0432.ccr-26-2348
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Molecular Features Underlying Discordance Between Clinical and Genomic Risk Stratification in Localized Prostate Cancer in Over 280, 000 Patients

Gerhardt Attard, Krishnan R. Patel, Edward M. Schaeffer, Elai Davicioni et al.
3 links
Clinical Cancer Research
Prostate Cancer Treatment and Research
article

Molecular Features Underlying Discordance Between Clinical and Genomic Risk Stratification in Localized Prostate Cancer in Over 280, 000 Patients

Gerhardt Attard, Krishnan R. Patel, Edward M. Schaeffer, Elai Davicioni, Adam Benjamin Weiner, Michael J. Zelefsky, Mohammed Alshalalfa, Ashley Evan Ross, Angela Y. Jia, Himanshu Nagar, Hyunnam Monica Ryu, Tyler M. Seibert, Phuoc Tho Tran, Xin Zhao, Qi Xu, Sarah Howlett, Yang Liu, Daniel Eidelberg Spratt, Michael Leapman, Melvin L.K. Chua, David R. Wise, Matthew R. Cooperberg, James A. Proudfoot, Marla K. Johnson
article en

Abstract

INTRODUCTION: Although the Decipher Genomic Classifier (GC) improves risk stratification beyond standard National Comprehensive Cancer Network (NCCN) risk groups, distinct clinical discordance exists between them. Herein, we interrogate specific adverse molecular features (AMFs) associated with genomic upgrading/downgrading relative to clinical risk and evaluate their overall long-term prognostic impact on treated patients. MATERIALS AND METHODS: The specific prevalence of four separate AMFs (TP53 status, PTEN inactivation, lower androgen receptor [AR] activity, and RB1 loss) was evaluated across GC and NCCN risk groups using biopsy data from 287,145 patients. Prognostic associations with distant metastasis (DM) were fully assessed in 15,109 patients with NCCN high and very high-risk disease. RESULTS: Decipher re-classified 21% of NCCN low and favorable intermediate-risk patients as high risk, while 33% of NCCN high-risk patients were GC-lower risk. AMF prevalence associated more strongly with GC than NCCN groups. TP53 mutant-like status, PTEN inactivation, and lower AR activity were associated with NCCN-GC discordance. Within the study cohort, a high GC score was associated with significantly increased risk of DM; AMFs independently predicted DM. Patients with at least one adverse AMF and a GC score >0.60 had a predicted 5-year DM probability of 17-25%, compared to 5% for those with favorable molecular profiles and a GC score ≤0.60. CONCLUSIONS: Individual AMFs are associated with the discordance between NCCN and GC risk classifications. In patients with NCCN high-risk disease, the GC score serves as a primary prognostic driver, while AMF profiling provides additive risk stratification within specific clinical GC strata.

Clinical Cancer Research
Northwestern University (US), University of Maryland, Baltimore (US), Cedars-Sinai Medical Center (US), Memorial Sloan Kettering Cancer Center (US), The University of Texas MD Anderson Cancer Center (US), University of California, San Francisco (US), University Hospitals of Cleveland (US), Yale University (US), University of California San Diego (US), NYU Langone Health (US), Northwestern University (PH), University Hospitals Cleveland Medical Center (US), Veracyte (United States) (US), National Cancer Centre Singapore (SG), The London College (GB), Northwestern Medicine (US), University College London (GB), University of Maryland, College Park (US), University of San Francisco (US)
Good health and well-being
Prostate Cancer Treatment and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon